Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space

Company’s synthetic affinity reagents are antibody alternatives designed to advance the speed, safety, and efficiency of manufacturing at scale, making advanced therapies more accessible to patients.

From MIP Discovery 20 Feb 2024

First gene therapy trial aims to restore hearing in children

The aim of this clinical trial, which has just received approval in France, is to assess the safety and efficacy of a new gene therapy drug in children aged between 6 and 31 months with profound hearing loss.

5 Feb 2024

CRISPR revolutionized: New method edits genes directly in the body

Most approved gene therapies today, including those involving CRISPR-Cas9, work their magic on cells removed from the body, after which the edited cells are returned to the patient.

1 Feb 2024

Gene therapy could prolong survival in some people with arrhythmogenic right ventricular cardiomyopathy

A new study in mice shows that replacement of a dysfunctional gene could prolong survival in some people with arrhythmogenic right ventricular cardiomyopathy (ARVC), a rare inherited disorder in which the muscular walls of the heart progressively weaken and put patients at risk of dangerous irregular heartbeats.

30 Jan 2024

Study shows effectiveness of gene therapy in treating congenital deafness

A new study co-led by investigators from Mass Eye and Ear, a member of Mass General Brigham, demonstrated the effectiveness of a gene therapy towards restoring hearing function for children suffering from hereditary deafness.

24 Jan 2024

University of Oxford launches first-in-human trial of the ChAdOx1 NipahB vaccine

The University of Oxford has launched a new clinical trial to test a vaccine to protect people against deadly Nipah virus.

11 Jan 2024

Marking a vital milestone for Vertex and Charles River

Charles River’s Memphis facility approved to manufacture Vertex’s CASGEVY™ therapy, the world’s first gene-edited therapy targeting severe sickle cell disease

From Charles River 9 Jan 2024

Small molecule applications of process Raman spectroscopy

In this interview, Kevin Broadbelt of Thermo Fisher Scientific discusses the small molecule applications of process Raman spectroscopy.

From Thermo Fisher Scientific – Portable and Handheld Raman Spectroscopy 11 Dec 2023

Liver trigger holds the key to boosting gene therapy success

Indiana University School of Medicine researchers have uncovered vital insights regarding a liver trigger that blocks an undesired immune response from gene therapy, surprisingly resulting in the activation of specific immune cells, despite the liver's typical role in suppressing immune responses.

7 Dec 2023

Refeyn launches KaritroMP for rapid and reproducible characterization of large viral vectors

Refeyn, a leader in mass photometry technology, announces the launch of its macro mass photometry platform, KaritroMP.

From Refeyn 4 Dec 2023

New insights into how SARS-CoV-2 evades our immune system

This review in Cellular and Molecular Immunology delves into the innate immune response to SARS-CoV-2, exploring how the virus evades immunity and the potential role of innate immunity in long-COVID and vaccine responses, shedding light on future therapeutic strategies.

23 Nov 2023

CEPI and University of Oxford launch new project to initiate vaccine development against Junín virus

The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford today announced the launch of a new project to initiate early development of prototype vaccines against the Junín virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly hemorrhagic fevers with epidemic and pandemic potential.

6 Nov 2023

CRISPR gene editing study provides insights into how autism gene affects brain development

Researchers have used CRISPR gene editing, stem cells and human neurons to study the impact of a gene that is commonly mutated in autism.

5 Oct 2023

Maternal COVID-19 shots significantly lowered infant hospitalizations during Omicron wave

Study found that maternal COVID-19 vaccination during pregnancy significantly reduces the risk of COVID-19-related hospitalizations in infants under six months, particularly boosting protection during the first three months of life. With 78% of the hospitalized infants born to unvaccinated mothers, the research emphasizes the crucial role of maternal vaccination in safeguarding infants too young for vaccination.

2 Oct 2023

Study suggests antibodies triggered by COVID-19 mRNA vaccination may depend on prior infection history

Researchers evaluated distinct immune responses to mRNA and vector-based COVID-19 vaccines and natural SARS-CoV-2 infections.

17 Aug 2023

Adenovirus infection linked to rare blood clotting disorder

Platelets, or thrombocytes, are specialized cellular fragments that form blood clots when we get scrapes and traumatic injuries. Viral infections, autoimmune disease, and other conditions can cause platelet levels to drop throughout the body, termed thrombocytopenia.

10 Aug 2023

Is COVID-19 vaccination linked to psoriasis emergence or flare-ups?

Researchers explored the relationship between COVID-19 vaccination and psoriasis onset or exacerbation.

7 Aug 2023

Intranasally administered SARS-CoV-2 RBD-based nanoparticle vaccine provides protection against lung pathology and viral load

In a recent study, researchers working at Ohio State University in the United States of America (USA) developed an intranasal subunit vaccine.

2 Aug 2023

Penn Medicine researchers identify new therapeutic target for Alzheimer's disease

A gene encoding a protein linked to tau production-;tripartite motif protein 11 (TRIM11)-;was found to suppress deterioration in small animal models of neurodegenerative diseases similar to Alzheimer's disease (AD), while improving cognitive and motor abilities, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

27 Jul 2023

Gene Therapy Contract Development and Manufacturing: Challenges and Future Perspectives

In this interview conducted at the Cell and Gene Therapy Summit Tour London, we speak to Ramin Baghirzade, Global Head of Commercial at Charles River for Gene Therapy, about the Gene Therapy CDMO solutions that Charles River Laboratories offers and more.

From Charles River Laboratories, Inc. 18 Jul 2023